.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average consequence of 11 months, people with metastatic gastrointestinal growths who received biomarker-matched treatments based on flowing lump DNA profiling presented a greater scientific benefit than those receiving unparalleled treatment.